Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPD | P32754 | 10/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282176 | 0.85 | CNR2 (0.50) | KDM4EHPDKMT2AALDH1A1HPGD | |
| SCHEMBL6205386 | 0.80 | HPD (0.58) | SLC22A12KDM4EHPDKMT2AALDH1A1 | |
| SCHEMBL6243978 | 0.73 | BCHE (0.58) | CNR1CNR2 | |
| SCHEMBL474533 | 0.73 | ALDH1A1 (0.46) | SLC22A12KDM4EHPDMEN1KMT2A | |
| SCHEMBL1422842 | 0.71 | SMN1; SMN2 (0.71) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6044123 | 0.70 | HCAR3 (0.73) | HPGD | |
| SCHEMBL24815336 | 0.70 | SLC22A12 (0.57) | SLC22A12B3GNT2KDM4EHPDMEN1 | |
| SCHEMBL27446319 | 0.70 | HPD (0.62) | SLC22A12B3GNT2KDM4EHPDMEN1 | |
| SCHEMBL30049030 | 0.70 | SLC22A12 (0.57) | SLC22A12B3GNT2KDM4EHPDMEN1 | |
| SCHEMBL14802479 | 0.69 | ALDH1A1 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| CN-1325376-A | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2001-12-05 | — | — | CN | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | SLC22A12 784/4885B3GNT2 796/4885KDM4E 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.